Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2007; 49:1525-1532, doi:10.1016/j.jacc.2006.12.038 (Published online 26 March 2007).
© 2007 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Khan, S. Q.
Right arrow Articles by Ng, L. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Khan, S. Q.
Right arrow Articles by Ng, L. L.

Prognostic Value of Midregional Pro-Adrenomedullin in Patients With Acute Myocardial Infarction

The LAMP (Leicester Acute Myocardial Infarction Peptide) Study

Sohail Q. Khan, BSc (Hons), MBChB, MRCP*,*, Russell J. O'Brien, MBChB, MRCP*, Joachim Struck, PhD{dagger}, Paulene Quinn, MPhil*, Nils Morgenthaler, PhD{dagger}, Iain Squire, MD, FRCP*, Joan Davies, PhD, FRCP*, Andreas Bergmann, PhD{dagger} and Leong L. Ng, MD, FRCP*

* University of Leicester, Department of Cardiovascular Sciences, Leicester Royal Infirmary, Leicester, United Kingdom
{dagger} Research Department, BRAHMS Aktiengesellschaft, Hennigsdorf, Germany


Figure 1
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 1 Principle of the MR-proADM Assay

A sketch of the adrenomedullin (ADM) precursor is shown, and amino acid positions in preproADM are denoted at which the precursor is proteolytically processed. Tracer- and solid phase–antibodies used in the sandwich immunoassay for the detection of midregional pro-adrenomedullin (MR-proADM) are indicated. PAMP = pro-adrenomedullin N-terminal 20 peptide; signal = signal peptide.

 

Figure 2
View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 2 Combined ROC Curve

Receiver-operating characteristic (ROC) curve comparing N-terminal pro-B-type natriuretic peptide (NTproBNP), midregional pro-adrenomedullin (MR-proADM), and the combined predicted probabilities from a binary logistic model for prediction of death or heart failure.

 

Figure 3
View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 3 Kaplan-Meier Curve: MR-proADM

Time to death or heart failure related to plasma midregional pro-adrenomedullin (MR-proADM).

 

Figure 4
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 4 Kaplan-Meier Curve: NTproBNP

Time to death or heart failure related to plasma N-terminal pro-B-type natriuretic peptide (NTproBNP).

 

Figure 5
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 5 Kaplan-Meier Curve: MR-proADM Quartiles Stratified by NTproBNP

Quartiles of MR-proADM are shown predicting the primary end point of death or heart failure in patients stratified by NTproBNP less than or greater than the median. Abbreviations as in Figure 2.

 

Figure 6
View larger version (28K):
[in this window]
[in a new window]
[Download PPT slide]
 
Figure 6 Three-Dimensional Bar Chart

Annual event rates for death and for death or heart failure in patients stratified by NTproBNP less than or greater than the median and by MR-proADM quartiles.Abbreviations as in Figure 2.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement